Close X
Attorney Spotlight

Find out which two countries Cheryl Palmeri gets the most questions about related to International Trade in today's market? Find out more>


Close X


Search our Experience

Experience Spotlight

In June 2016, AmSurg Corp. and Envision Healthcare Holdings, Inc. (Envision) announced they have signed a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction. Upon completion of the merger, which is expected to be tax-free to the shareholders of both organizations, the combined company will be named Envision Healthcare Corporation and co-headquartered in Nashville, Tennessee and Greenwood Village, Colorado. The company's common stock is expected to trade on the New York Stock Exchange under the ticker symbol: EVHC. Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Read more.

AmSurg logo

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Inside the FCA blogInside the FCA blog features ongoing updates related to the False Claims Act (FCA), including insight on the latest legal decisions, regulatory developments and FCA settlements. The blog provides timely updates for corporate boards, directors, compliance managers, general counsel and other parties interested in the organizational impact and legal developments stemming from issues potentially giving rise to FCA liability.

Read More >

Steele Clayton Interviews FTC Bureau of Competition Director Richard Feinstein

Media Mentions

January 8, 2010

Steele Clayton, attorney at Bass, Berry & Sims and assistant leader of the firm's Antitrust & Trade Practices Group, along with Toby Singer of Jones Day in Washington, D.C., has conducted an interview with Federal Trade Commission Bureau of Competition Director Richard Feinstein for the American Health Lawyers Association Practice Group Member Briefing.

The interview is described as follows:

The Obama Administration is still just beginning to put its stamp on the federal antitrust enforcement agencies. But new appointees at the Federal Trade Commission (FTC) have signaled that they will continue the FTC's strong emphasis on antitrust enforcement in the healthcare arena. FTC Director of the Bureau of Competition Richard Feinstein has particular expertise in healthcare antitrust, having served as assistant director for the Health Care Services and Products Division of the Bureau of Competition in the Clinton Administration, and having continued to practice healthcare antitrust law in private practice after his government service. The AHLA Antitrust Practice Group posed a set of questions to Mr. Feinstein to elicit his views on healthcare antitrust enforcement policy for the FTC now and in the future. Access the Member Briefing entitled, "Questions for Richard Feinstein, Director of the Bureau of Competition at the Federal Trade Commission," which contains the transcript of the interview.

There are a number of responses of particular interest. Mr. Feinstein characterizes one of the FTC's top priorities as "aggressive" merger enforcement. He explains what we can expect to see in future hospital merger challenges, both procedurally and substantively. He warns against adopting the view that concentration in insurer markets justifies further concentration in provider markets, and states that the FTC examines physician group mergers in the same way that it examines other types of mergers. With respect to clinical integration, Mr. Feinstein reveals that there is more guidance on the way and that the FTC will be having more discussions with groups interested in clinical integration. Other issues addressed are FTC Act Section 5 enforcement, efforts to amend the antitrust laws, and more.

In Case You Missed It:

Related Professionals

Related Services


Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.